Genmab A/S (GMAB) Competitors

Takeda Pharmaceutical (NYSE:TAK) and Genmab A/S (NASDAQ:GMAB) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, profitability, risk and institutional ownership.

Does the media refer more to TAK or GMAB?

In the previous week, Takeda Pharmaceutical had 2 more articles in the media than Genmab A/S. MarketBeat recorded 12 mentions for Takeda Pharmaceutical and 10 mentions for Genmab A/S. Genmab A/S's average media sentiment score of 0.58 beat Takeda Pharmaceutical's score of 0.49 indicating that Genmab A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Takeda Pharmaceutical	3 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Genmab A/S	4 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more volatility and risk, TAK or GMAB?

Takeda Pharmaceutical has a beta of 0.22, suggesting that its stock price is 78% less volatile than the S&P 500. Comparatively, Genmab A/S has a beta of 0.95, suggesting that its stock price is 5% less volatile than the S&P 500.

Do analysts rate TAK or GMAB?

Genmab A/S has a consensus price target of $37.80, suggesting a potential upside of 73.55%. Given Genmab A/S's higher probable upside, analysts clearly believe Genmab A/S is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Takeda Pharmaceutical	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Genmab A/S	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64

Which has higher earnings and valuation, TAK or GMAB?

Genmab A/S has lower revenue, but higher earnings than Takeda Pharmaceutical. Genmab A/S is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Takeda Pharmaceutical	$30.09B	1.50	$712.33M	$0.30	47.23
Genmab A/S	$3.12B	4.48	$1.14B	$1.76	12.38

Is TAK or GMAB more profitable?

Genmab A/S has a net margin of 35.11% compared to Takeda Pharmaceutical's net margin of 3.20%. Genmab A/S's return on equity of 18.08% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Takeda Pharmaceutical	3.20%	10.50%	5.10%
Genmab A/S	35.11%	18.08%	14.52%

Do insiders and institutionals have more ownership in TAK or GMAB?

9.2% of Takeda Pharmaceutical shares are held by institutional investors. Comparatively, 7.1% of Genmab A/S shares are held by institutional investors. 0.0% of Takeda Pharmaceutical shares are held by company insiders. Comparatively, 1.5% of Genmab A/S shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Genmab A/S beats Takeda Pharmaceutical on 12 of the 17 factors compared between the two stocks.